Total Payments
$964,284
2024 Payments
$246,121
Companies
78
Transactions
2,337
Medicare Patients
893
Medicare Billing
$99,474
Payment Breakdown by Category
Other$715,121 (74.2%)
Consulting$117,728 (12.2%)
Travel$71,074 (7.4%)
Food & Beverage$50,165 (5.2%)
Research$9,667 (1.0%)
Education$529.60 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $703,221 | 265 | 72.9% |
| Consulting Fee | $117,728 | 46 | 12.2% |
| Travel and Lodging | $71,074 | 338 | 7.4% |
| Food and Beverage | $50,165 | 1,664 | 5.2% |
| Honoraria | $11,900 | 4 | 1.2% |
| Unspecified | $9,667 | 11 | 1.0% |
| Education | $529.60 | 9 | 0.1% |
Payments by Type
General
$954,617
2,326 transactions
Research
$9,667
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $223,050 | 343 | $0 (2024) |
| Biogen, Inc. | $168,092 | 276 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $78,970 | 91 | $0 (2024) |
| TG Therapeutics, Inc. | $76,172 | 88 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $75,397 | 135 | $0 (2023) |
| GENZYME CORPORATION | $63,493 | 130 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $61,039 | 268 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $58,569 | 98 | $0 (2024) |
| Genentech USA, Inc. | $53,378 | 115 | $0 (2024) |
| Horizon Therapeutics plc | $24,715 | 43 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $246,121 | 429 | EMD Serono, Inc. ($79,115) |
| 2023 | $185,112 | 370 | EMD Serono, Inc. ($66,519) |
| 2022 | $240,215 | 491 | Biogen, Inc. ($55,853) |
| 2021 | $138,946 | 361 | Biogen, Inc. ($42,512) |
| 2020 | $54,208 | 275 | EMD Serono, Inc. ($13,505) |
| 2019 | $93,101 | 317 | Novartis Pharmaceuticals Corporation ($31,995) |
| 2018 | $5,983 | 86 | Genentech USA, Inc. ($3,597) |
| 2017 | $597.57 | 8 | Novartis Pharmaceuticals Corporation ($328.35) |
All Payment Transactions
2,337 individual payment records from CMS Open Payments — Page 1 of 94
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,835.00 | General |
| Category: Neuroscience | ||||||
| 12/20/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 12/20/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $70.21 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $28.81 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 12/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $301.86 | General |
| Category: Immunology | ||||||
| 12/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $254.60 | General |
| Category: Immunology | ||||||
| 12/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | Cash or cash equivalent | $26.16 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $0.94 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $0.39 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/17/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: PAIN | ||||||
| 12/16/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $6.75 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Immunology | ||||||
| 12/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $9.52 | General |
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,463.00 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Neurology | ||||||
| 12/04/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $10.15 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/03/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,110.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Biogen, Inc. | VUMERITY (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KESIMPTA Study Related Review Article Writing Support | Novartis Pharmaceuticals Corporation | $8,289 | 1 |
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $1,377 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 203 | 279 | $55,875 | $20,640 |
| 2022 | 3 | 216 | 315 | $68,926 | $25,917 |
| 2021 | 6 | 226 | 335 | $58,053 | $24,973 |
| 2020 | 7 | 248 | 386 | $61,788 | $27,944 |
Total Patients
893
Total Services
1,315
Medicare Billing
$99,474
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 100 | 148 | $23,748 | $8,518 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 55 | 83 | $19,963 | $7,509 | 37.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 30 | 30 | $7,052 | $2,781 | 39.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $5,112 | $1,832 | 35.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 95 | 164 | $39,707 | $15,280 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 83 | 113 | $17,897 | $6,564 | 36.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 38 | 38 | $11,322 | $4,072 | 36.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 125 | 222 | $33,078 | $14,345 | 43.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 33 | 41 | $9,389 | $3,822 | 40.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $5,112 | $2,442 | 47.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 16 | $4,496 | $2,168 | 48.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 21 | 21 | $4,788 | $1,944 | 40.6% |
| 92133 | Diagnostic imaging of optic nerve of eye | Facility | 2021 | 16 | 17 | $1,190 | $253.05 | 21.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 119 | 226 | $33,674 | $15,603 | 46.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 37 | $6,808 | $3,011 | 44.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 21 | 24 | $5,496 | $2,584 | 47.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 22 | 22 | $5,016 | $2,365 | 47.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 17 | 17 | $4,828 | $2,253 | 46.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 14 | $2,086 | $864.08 | 41.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 22 | $2,200 | $842.27 | 38.3% |
| 92133 | Diagnostic imaging of optic nerve of eye | Facility | 2020 | 24 | 24 | $1,680 | $421.28 | 25.1% |
About Dr. William Conte, M.D
Dr. William Conte, M.D is a Neurology healthcare provider based in Merrillville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/19/2013. The National Provider Identifier (NPI) number assigned to this provider is 1467794271.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Conte, M.D has received a total of $964,284 in payments from pharmaceutical and medical device companies, with $246,121 received in 2024. These payments were reported across 2,337 transactions from 78 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($703,221).
As a Medicare-enrolled provider, Conte has provided services to 893 Medicare beneficiaries, totaling 1,315 services with total Medicare billing of $99,474. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Merrillville, IN
- Active Since 03/19/2013
- Last Updated 02/28/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1467794271
Products in Payments
- Mavenclad (Drug) $132,553
- ZEPOSIA (Drug) $87,847
- BRIUMVI (Drug) $76,055
- VUMERITY (Drug) $71,280
- TYSABRI (Biological) $43,905
- OCREVUS (Biological) $43,609
- MAYZENT (Drug) $40,956
- Ponvory (Drug) $40,308
- MAVENCLAD (Drug) $27,856
- UPLIZNA (Drug) $24,715
- SOLIRIS (Drug) $17,509
- Mavenclad (Biological) $16,292
- KESIMPTA (Drug) $15,557
- BAFIERTAM (Drug) $13,005
- Evobrutinib $9,600
- UBRELVY (Drug) $9,080
- DISEASE STATE (Drug) $8,200
- AUBAGIO (Drug) $7,812
- PONVORY (Drug) $7,668
- Ocrevus (Biological) $6,970
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Merrillville
Richard Cristea, M.d, M.D
Neurology — Payments: $28,002
Neurology $28,002
Louis Teodori, D.o, D.O
Neurology — Payments: $8,843
Neurology $8,843
Jennifer Pallone, D.o, D.O
Neurology — Payments: $6,074
Neurology $6,074
Dr. Raul Guevara, M.d, M.D
Neurology — Payments: $1,173
Neurology $1,173
Emilio Soria, M.d, M.D
Neurology — Payments: $366.31
Neurology $366.31